Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 30:4:30.
doi: 10.1038/s41392-019-0064-7. eCollection 2019.

The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer's disease and vascular dementia: focusing on fluoxetine with long follow-up periods

Yi Xie  1   2 , Pei-Pei Liu  1 , Ya-Jun Lian  2 , Hong-Bo Liu  2 , Jian-Sheng Kang  1
Affiliations

The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer's disease and vascular dementia: focusing on fluoxetine with long follow-up periods

Yi Xie et al. Signal Transduct Target Ther. .
No abstract available

Keywords: Neurological disorders; Neuroscience.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Forest plot of comparisons. a Forest plot of age comparison; there is no age difference between the SSRI and placebo groups (MD = −0.86, 95% CI: −1.76–0.03, P = 0.06). No significant heterogeneity existed (I2 = 0%, P = 0.89) b Forest plot of overall MMSE; there was a significant difference between the SSRI and placebo groups (MD = 0.84, 95% CI: 0.32–1.37, P = 0.002). c Fluoxetine significantly improved cognitive function in clinical practice (MD = 1.16, 95% CI: 0.41–1.90, P = 0.002). Significant heterogeneity existed (I2 = 88%, P < 0.00001). d There was no significant difference between nonfluoxetine SSRIs versus the placebo (MD = 0.58, 95% CI: −0.17–1.33, P = 0.13)
See this image and copyright information in PMC

References

    1. Li XS. The curative effects of fluoxetine on vascular dementia. J. Linyi Med. Coll. 2005;27:435–437.
    1. Mowla A, Mosavinasab M, Haghshenas H, Haghighi AB. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial. J. Clin. Psychopharmacol. 2007;27:484–487. doi: 10.1097/jcp.0b013e31814b98c1. - DOI - PubMed
    1. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J. Clin. Psychopharmacol. 2007;27:67–70. doi: 10.1097/JCP.0b013e31802e0002. - DOI - PubMed
    1. Zhao RX, Ren AH. Effect of different doses of fluoxetine in the treatment of vascular dementia. J. Huaihai Med. 2009;27:425.
    1. Liu X, et al. Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. Clin. Interv. Aging. 2014;9:411–418. - PMC - PubMed

Publication types